01—Abstract
Summary
Summary of the 8-K filed April 21, 2025. Cited figures are marked; the original filing is the authoritative source.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported first-quarter 2025 results on April 21, 2025.
Revenue rose 9.3% to $558.6 milliona from $511.0 million, and GAAP net income was $114.6 million, or $3.67 per diluted share, versus $102.6 million, or $3.20 per diluted share, a year earlier. EBITDA increased 2.6% to $118.6 million, with the EBITDA margin falling to 21.2% from 22.6%. Net new business awards declined 18.8% to $500.0 million, resulting in a net book-to-bill ratio of 0.90x, and backlog decreased 2.1% to $2,846.0 million as of March 31, 2025.
The company ended the quarter with $441.4 millionb in cash and cash equivalents and generated $125.8 million in operating cash flow. During the quarter it repurchased 1,193,011 shares at an average price of $326.78 for a total of $389.8 million. On April 17, 2025, the Board approved a $1.0 billion increase to the stock repurchase program, and $344.8 million remained under the program as of March 31, 2025.
Separately, on April 18, 2025, the company's subsidiaries entered into Amendment No. 8 to the loan documents for its unsecured credit facility with PNC Bank, National Association, which increases the line of credit to up to $600 millionc, adjusts the interest rate and extends the revolving credit note's expiration to April 30, 2027. For 2025, the company forecasts revenue of $2.140 billion to $2.240 billion, representing growth of 1.5% to 6.2% over 2024 revenue of $2.109 billion.
It guides to GAAP net income of $378.0 million to $402.0 milliond, EBITDA of $462.0 million to $492.0 million, and diluted EPS of $12.26 to $13.04. The guidance assumes a tax rate of 15.5% to 16.5%, interest income of $15.8 million and 30.8 million diluted shares, and it excludes any repurchases made after March 31, 2025.
02—Key points
Key Highlights
- Q1 2025 revenue grew 9.3% to $558.6 million; constant currency revenue growth was 9.5%.
- GAAP net income rose to $114.6 million ($3.67 per diluted share) from $102.6 million ($3.20 per diluted share); net income margin was 20.5% versus 20.1%.
- Net new business awards fell 18.8% to $500.0 million, giving a net book-to-bill ratio of 0.90x; backlog declined 2.1% to $2,846.0 million.
- EBITDA increased 2.6% to $118.6 million, but the EBITDA margin declined to 21.2% from 22.6%.
- Board approved a $1.0 billion increase to the stock repurchase program on April 17, 2025; $344.8 million remained under the prior program at March 31, 2025.
- Amendment No. 8 raises the PNC unsecured credit facility line of credit to up to $600 million and extends the revolving credit note expiration to April 30, 2027.
- 2025 guidance: revenue of $2.140 billion to $2.240 billion, GAAP net income of $378.0 million to $402.0 million, and EBITDA of $462.0 million to $492.0 million.
03—Questions
Frequently Asked Questions
How did Medpace perform in the first quarter of 2025?
Revenue increased 9.3% to $558.6 million, GAAP net income rose to $114.6 million ($3.67 per diluted share) from $102.6 million ($3.20 per diluted share), and EBITDA grew 2.6% to $118.6 million. Net new business awards decreased 18.8% to $500.0 million.
Why did the EBITDA margin decline even though EBITDA increased?
The filing reports EBITDA margin of 21.2% for the first quarter of 2025, compared with 22.6% in the prior-year period, while EBITDA itself rose 2.6%. The press release does not give a specific explanation for the margin change beyond these figures.
What is the company's share repurchase situation?
In the first quarter, Medpace repurchased 1,193,011 shares at an average price of $326.78 for a total of $389.8 million, leaving $344.8 million remaining under its program at March 31, 2025. On April 17, 2025, the Board approved a $1.0 billion increase to the program. Repurchases may be made in the open market, in privately negotiated transactions or under a Rule 10b5-1 plan, and the program may be discontinued or amended at any time.
What changed in the company's credit facility?
Under Amendment No. 8 dated April 18, 2025, with PNC Bank, National Association, the line of credit can be borrowed up to $600 million, the interest rate charged on the facility was adjusted, and the revolving credit note's expiration was extended to April 30, 2027.
What is the company's 2025 outlook?
Medpace forecasts 2025 revenue of $2.140 billion to $2.240 billion, GAAP net income of $378.0 million to $402.0 million, EBITDA of $462.0 million to $492.0 million and diluted EPS of $12.26 to $13.04. The guidance assumes a 15.5% to 16.5% tax rate and 30.8 million diluted shares, and excludes share repurchases made after March 31, 2025.
04—Continue